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Abstract 
Objective: The aim of this study was to measure the level of Vitamin K2 (Vit K2) in osteoporotic patients and 
individuals with normal bone density as controls. 
Materials and Methods: This case-control study was done in Outpatient Department of Rheumatology at 
Qazvin Boo-ali Sina Hospital in 2013. Participants were 50 patients with osteoporotic densitometry measured by 
DEXA (T score≤ -2.5) who were matched with 48 persons in control group with normal bone density (T score> 
-1). The level of Vit K2 in samples was measured using enzyme linked immunosorbent assay (ELISA). Data 
were analyzed by Mann-Whitney U test and Chi-square test. 
Results: The level of Vit K2 in patients with osteoporosis was not significantly different from the control group 
(Median: 75.95 vs. 71.35 nmol/L, respectively; P-value: 0.709). The authors determined cut-offs 75 percentile of 
vitamin K2 in all participants that was 85 nmol/L and percentages of persons in two groups were similar. 
Conclusion: Although Vit K2 level in patients with osteoporosis was not significantly different from the control 
group, further studies are necessary to confirm the association of osteoporosis and Vit K2.  
Keywords: bone densitometry, normal bone density, osteoporosis, vitamin K2 
1. Introduction 
Vitamin K (Vit K) is a fat soluble vitamin which is categorized to, phylloquinone (K1), menaquinones (K2) and 
Menadione (K3) (Plaza & Lamson, 2005). Phylloquinone (K1) family, also known as phytonadione based on 
relation to photosynthesis, is well known. The resources of Vit K1 are higher plants and green leafy vegetables 
(Shearer, 1995). Menaquinones (K2) produced naturally in a production series by intestinal bacteria and, not by 
higher plants (Plaza & Lamson, 2005).  
Vit K deficiency is uncommon in healthy adults because: 1) Vit K is widespread in foods, 2) the Vit K cycle 
conserves it; and 3) bacteria in the large intestine usually synthesize menaquinones (Vitamin K2), but it is 
unclear whether significant amounts of produced Vit K2 are absorbed and utilized. The risk of Vit K deficiency 
is increased in patients who are taking Vit K antagonist like anticoagulant drugs, and individuals with significant 
liver damage or disease (Olson, 1999). As well, individuals with fat malabsorption disorders may be at higher 
risk of Vit K deficiency (Ferland, 2006). Exogenous Vit K is required for carboxylation of osteocalcin, which in 
turn allows osteocalcin to bind to hydroxyapatite mineral. A Vitamin K2 (Vit K2) preparation (menatetrenone) is 
widely used for treatment of osteoporosis in Japan (Rosen & Drezner, 2014). Observational data suggest that low 
vitamin K consumption or impaired Vit K status may be associated with an increased risk of fracture in elderly 
(Feskanich et al., 1999; Booth et al., 2004). 
Seven clinical trials in Japan (primarily on postmenopausal women with osteoporosis) reported fracture data; and 
then used menaquinone for prevention of osteoporotic fractures. After administration of Vit K2, significant 
decrease was seen in vertebral, hip, and all non-vertebral fractures (Brar, 2010). It must be considered that these 
reports are only in Japanese women, who may have significant dietary differences from other countries (Brar, 
2010). The aim of this study was to measure the levels of Vit K2 in individuals with normal bone density and 
osteoporotic patients. 
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2. Methods 
In this case-control study, the osteoporotic women with low bone density (T-score ≤ 2.5 score) who were 
attending at outpatient rheumatology clinic of Boo-ali Sina hospital from June 2012 to March 2013 were 
compared with normal patients who were referred to this clinic for other problems unrelated to rheumatologic 
diseases. The control group had normal bone density during the same period. The study was approved by the 
ethics committee of Qazvin University of Medical Sciences. All participants signed the written informed consent 
and they could leave the study whenever wished.  
The sample size was calculated using the following formula: 
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Considering α: 0.05 , β: 20% , ∆: 200 , µ1: 700 and µ2: 490 based on a pilot study by the authors, the calculated 
sample size was 40 for each group. This study was conducted in 50 osteoporotic patients and 48 healthy controls 
that were matched for age, gender, and socioeconomic status. Bone densitometry was done by DXA. In 
osteoporotic cases the range of T-score was found to be -2.5 to -4.1 in vertebra and -2.5 to -5.3 in femur while in 
normal cases the range of T-score was +1 to -0.9 in vertebra and femur.  
 
T-Score Diagnosis
Normal 0 to -1 
Osteopenic -1 To -2.5
Osteoporosis ≤ -2.5 
 
Patients who were taking medications such as Aspirin, Cholestyramine, Phenytoin, or those who were taking 
broad-spectrum antibiotics for a long time as well as patients with liver disease and malabsorption were excluded 
from the study. 
Two milliliters of peripheral venous blood were collected after 8 hour fasting from each participant. The 
measurement of Vit K2 was achieved by commercial ELISA kit based on its protocol (Glory science Co., Ltd: 
U.S.A.).  
Kolmogorov Smirnov test was used to examine the normality of variables. Data were reported as median 
(minimum, maximum) or in number (percent). Variables were compared between the patients and the controls 
using Mann-Whitney U test or a Chi-square test. P-value < 0.05 was considered to be significant.  
3. Results 
In this case-control study, results of Vit K2 were compared in two groups. Fifty patients with osteoporotic bone 
density (T-score ≤ -2.5) and 48 age-matched persons as controls with normal bone density (T-score> -1) have 
attended. Table 1 has shown the demographic characteristics and Vit K2 level. Vit K2 level was not significantly 
different between two groups.  
In addition, the authors determined cut-offs 75 percentile of vitamin K2 in all participants that was 85 nmol/L. 
Table 2 demonstrates that the same as previous table, percentages of persons in two groups were similar. 
Furthermore, we got interested to analyze Vit K2 in two groups based on categorized BMI and age. Table 3 
shows that the level of Vit K2 in BMI of 25-30 was more than the others, however, this difference was not 
statistically significant between two groups.  
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Table 1. Demographic characteristics and Vitamin K2 levels of participants in two groups 
  
Case group  
(N: 50) 
Control group  
(N: 48) 
P-value 
Gender a 
Male 1(2.0) 3(6.2) 
NS 
Female 49(98.0) 45(93.8) 
Job a 
Employment 8(16) 7(14.6) 
NS Household 41(82) 40(83.4) 
Retired 1(2) 1(2) 
Marriage Status a 
Single 4(8) 6(12.5) 
NS 
Married 46(92) 42(87.5) 
Age a 
30-49 3(6) 7(14.6) 
NS 50-69 43(86) 39(81.2) 
≥70 4(8) 2(4.2) 
BMI a 
<25 14(31.1) 8(19.5) 
NS 25-30 18(40) 15(36.6) 
>30 13(28.9) 18(43.9) 
Education a 
Uneducated 12(24) 9(18.8) 
NS <12 years 25(50) 28(58.3) 
>12 years 13(26) 11(22.9) 
Vit K2 b  75.95 (26.8-341.1) 71.35 (37.8- 498.6) NS 
a data are presented as number (percent);b Data are presented as median (min - max); NS: not significant. 
 
Table 2. Comparison of participants based on the cut-offs 75 percentile 
 
Case group 
N (%) 
Control group 
N (%) 
P -value
Vit K2 < 85 39(78.0) 36 (75.0) 
0.813 
Vit K2 > 85 11(22.0) 12(25.0) 
 
Table 3. Comparison of vitamin K2 in two groups based on categorized BMI and age 
    Median Min Max P-value 
Vit K2 
BMI 
<25 
Case 75.95 52.9 341.1 
0.539 
Control 72.15 50.2 498.6 
25-30 
Case 82.1 26.8 314.3 
0.563 
Control 84.4 58.0 305.7 
>30 
Case 73.1 48.2 171.5 
0.734 
Control 71.2 48.2 439.5 
Age 
30-49 
Case 66.0 48.8 72.9 
0.206 
Control 77.1 43.3 498.6 
50-69 
Case 77.0 26.8 341.1 
0.726 
Control 72.1 37.8 439.5 
≥70 Case 83.1 63.0 111.5 0.165 
Control 56.6 48.2 65.0 
 
4. Discussion 
Like other fat-soluble vitamins, absorption of Vit K depends on bile salts, so the clinical assessment of Vit K is 
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important in patients with malabsorption syndromes and liver diseases. Assessment of Vit K in plasma is difficult 
because it is in nanosmolar concentrations (Thane, 2002; McKeown et al., 2002; Booth et al., 1997). Large 
differences in average levels of Vit K have been reported in different populations which explain the range of 0.22 
to 8.88 nmol/L. (Azharuddin, O'Reilly, Gray, & Talwar, 2007). Recently several methods for direct and accurate 
measurement of all types of Vit K in blood circulation have been developed (Suhara, Kamao, Tsugawa, & Okano, 
2005; Booth, Lichtenstein, & Dallal, 2002). Vit K acts as a cofactor for carboxylase enzyme. This allows the 
protein with high affinity for calcium ions to bind to osteocalcin. Vit K dependent carboxylation allows proteins 
to bind to hydroxyapatite (Hoang, Sicheri, Howard, & Yang, 2003). 
In recent years, many studies about Vit K2 and its role in osteoporosis were taken. Several Japenese studies 
showed that Vit K2 in patients with osteoporosis is low and giving Vit K2 to them increases bone density (Rosen 
& Drezner, 2014). Several studies in different countries have been performed about the effect of Vit K2 in 
osteoporotic patients and its effect on bone density. In some of these studies, it is suggested that Vit K2 has 
positive impact on osteoporosis, but others shows no effect (Rosen & Drezner, 2014; Feskanich, et al., 1999; 
Booth, et al., 2004; Cockayne et al., 2006). Observational data indicate that Vit K deficiency may be associated 
with an increased risk of fracture in older men and women (Rosen & Drezner, 2014; Feskanich et al., 1999; 
Booth et al., 2004). In our study; there is no significant difference in level of Vit K2 in osteoporotic patients than 
normal group.  
Vitamin K2 plays a role in bone formation. There are many studies on the effect of vitamin K2 on bone density 
and risk of bone fracture. But none of the recent studies assess the Vit K level in the serum of patients. Therefore 
we measured the serum level of Vit K2 in 50 osteoporotic patients and in 48 individuals with normal bone 
density. There was no significant difference between two groups. Also there was no significant difference in 
serum Vit K2 level in postmenopausal and nonmenopausal women. 
Vitamin K1 is found in leafy green vegetables particularly at high levels in plants but is found at low levels in 
meat and cheese and bread. Vit K2 is found in the meat, vegetable oils and cheeses. The food intakes of Vit K are 
high in western countries but not so in Japan (Booth, Pennington, & Sadowski, 1996).  
In a study performed on 381 menopausal women in North America, they were given Vit K2 or placebo for a 
period of 12 months. In the group who received Vit K2 no effect was found on BMD of the lumbar vertebra and 
femur (Binkley et al., 2009). Vitamin K2 is used extensively in Japan for the treatment of osteoporosis (Rosen & 
Drezner, 2014). Many studies about the efficacy of Vit K2 to increase the bone density were reported from Japan 
which are especially nutritional ones (Bolton-Smith et al., 2007). Therefore, those studies should be interpreted 
with caution. In a double–blind placebo-controlled study on nonosteoporotic postmenopausal women in North 
America, the aim was to evaluate the Vit K2 treatment on markers of skeletal turnover and BMD which showed 
no effect on BMD (Rosen & Drezner, 2014; Binkley et al., 2009; Booth et al., 1996). In a 3-yr double-blind 
study of 452 men and women between the age 60 to 80 years, they received a multivitamin which contained 
either 500 μg/d or no phylloquinone plus a daily calcium (600 mg elemental calcium) and vitamin D (400 IU) 
supplement and the treatment did not make any change in BMD of anatomical sites (Booth et al., 2008). In a 
study of postmenopausal Korean women, 78 postmenopausal women older than sixty years over the past 6 years 
were given Vit K along with vitamin D and calcium, which resulted in decreased serum level of 
undercarboxylated osteocalcin and led to increased bone mineral density (Je et al., 2011). Although Vit K2 level 
in patients with osteoporosis was not significantly different from the control group in the present study, further 
studies are necessary to confirm the association of osteoporosis and Vit K2.  
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